CARDIOVASCULAR DISEASES AS A COMPLICATION LEADING TO CHRONIC KIDNEY DISEASE: CLINICAL SIGNS, EARLY DIAGNOSIS, AND PREVENTION
Keywords:
type 2 cardiorenal syndrome, glomerular filtration rate, urinary albumin-to-creatinine ratio, sodium-glucose cotransporter 2 inhibitors, Dapagliflozin in Patients with Chronic Kidney Disease study, Empagliflozin in Patients with Chronic Kidney Disease study, finerenone, biomarkers, early screening, preventionAbstract
Cardiovascular diseases, particularly chronic heart failure, play a significant role in the development of chronic kidney disease (CKD) and constitute type 2 cardiorenal syndrome. According to Global Burden of Disease study data, chronic kidney disease ranks as the 9th leading cause of death worldwide, associated with 1.48 million deaths annually, and occupies the 12th position in terms of years lived with disability. In patients with CKD, the rate of cardiovascular complications and mortality can reach 40–50%. This article provides an in-depth analysis of the clinical manifestations of chronic kidney disease developing as a complication of cardiovascular diseases, the pathophysiological mechanisms of cardiorenal syndrome, its association with diabetes mellitus, methods of early diagnosis, and modern preventive measures.
References
. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. “Kidney Int”. 2024;105(4S):S117-S314. (Data mainly taken from pages S117–S314).
2. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. “N Engl J Med”. 2020;383(15):1436-1446. (Data mainly taken from pages 1436–1446).
3. EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. “N Engl J Med”. 2023;388(2):117-127. (Data mainly taken from pages 117–127).
4. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. “Circulation”. 2019;139(16):e840-e878. (Data mainly taken from pages e840–e878).
5. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. “N Engl J Med”. 2020;383(23):2219-2229. (Data mainly taken from pages 2219–2229).
6. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. “N Engl J Med”. 2021;385(24):2252-2263. (Data mainly taken from pages 2252–2263).
7. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. “J Am Coll Cardiol”. 2008;52(19):1527-1539. (Data mainly taken from pages 1527–1539).
8. Mark PB, et al. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023. “Lancet”. 2025 (based on general study results).
9. Levin A, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. “Kidney Int”. 2024;105(4S):S117-S314
